Anti-CD3 clinical trials in type 1 diabetes mellitus

Clinical Immunology

Volumn 149, Issue 3, 2013, Pages 268-278

  Daifotis, Anastasia G ^a   Koenig, Scott ^a   Chatenoud, Lucienne ^b   Herold, Kevan C ^c  

^a Analytical Sciences   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c YALE UNIVERSITY   (United States)

Author keywords

Anti CD3; Otelixizumab; Teplizumab; Type 1 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CHEMOKINE RECEPTOR CCR6; FC RECEPTOR; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 10; INTERLEUKIN 17; OTELIXIZUMAB; PLACEBO; TEPLIZUMAB; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

AGE DISTRIBUTION; ANEMIA; ANTIBODY BLOOD LEVEL; APOPTOSIS; AREA UNDER THE CURVE; ARTHRALGIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL DEATH; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DIABETIC KETOACIDOSIS; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; IN VITRO STUDY; INCIDENCE; INFECTION; INFUSION RELATED REACTION; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; LAMINA PROPRIA; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PATIENT MONITORING; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REPEATED DRUG DOSE; REVIEW; RIGOR; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA; VIREMIA; VIRUS REACTIVATION; VOMITING;

ANTI-CD3; OTELIXIZUMAB; TEPLIZUMAB; TYPE 1 DIABETES MELLITUS;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD3; C-PEPTIDE; CHILD; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; MIDDLE AGED; RECEPTORS, FC; T-LYMPHOCYTES;

EID: 84887025288     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.05.001     Document Type: Review

References (65)

1. Gepts W., Lecompte P.M. The pancreatic islets in diabetes. Am. J. Med. Jan 1981, 70(1):105-115.
2. Schranz D.B., Lernmark A. Immunology in diabetes: an update. Diabetes Metab. Rev. Mar 1998, 14(1):3-29.
3. Feutren G., Papoz L., Assan R., Vialettes B., Karsenty G., Vexiau P., et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet Jul 19 1986, 2(8499):119-124.
4. Silverstein J., Maclaren N., Riley W., Spillar R., Radjenovic D., Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N. Engl. J. Med. Sep 8 1988, 319(10):599-604.
5. Eisenbarth G.S., Srikanta S., Jackson R., Rabinowe S., Dolinar R., Aoki T., et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res. Nov 1985, 2(6):271-276.
6. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. Feb 2003, 3(2):123-132.
7. Chatenoud L., Thervet E., Primo J., Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. Jan 4 1994, 91(1):123-127.
8. Chatenoud L., Primo J., Bach J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. Mar 15 1997, 158(6):2947-2954.
9. Chatenoud L., Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. Aug 2007, 7(8):622-632.
10. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?. Nat. Rev. Endocrinol. Mar 2010, 6(3):149-157.
11. Alegre M.L., Vandenabeele P., Depierreux M., Florquin S., Deschodt-Lanckman M., Flamand V., et al. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. J. Immunol. Feb 15 1991, 146(4):1184-1191.
12. Chatenoud L., Ferran C., Legendre C., Thouard I., Merite S., Reuter A., et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation Apr 1990, 49(4):697-702.
13. Anderson M.S., Bluestone J.A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 2005, 23:447-485.
14. Alegre M.L., Tso J.Y., Sattar H.A., Smith J., Desalle F., Cole M., et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. Aug 1 1995, 155(3):1544-1555.
15. Herold K.C., Bluestone J.A., Montag A.G., Parihar A., Wiegner A., Gress R.E., et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes Mar 1992, 41(3):385-391.
16. Hirsch R., Bluestone J.A., DeNenno L., Gress R.E. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation Jun 1990, 49(6):1117-1123.
17. Sandborn W.J., Colombel J.F., Frankel M., Hommes D., Lowder J.N., Mayer L., et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut Nov 2010, 59(11):1485-1492.
18. Utset T.O., Auger J.A., Peace D., Zivin R.A., Xu D., Jolliffe L., et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. Sep 2002, 29(9):1907-1913.
19. Woodle E.S., Xu D., Zivin R.A., Auger J., Charette J., O'Laughlin R., et al. Phase 1 trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation Sep 15 1999, 68(5):608-616.
20. Alegre M.L., Collins A.M., Pulito V.L., Brosius R.A., Olson W.C., Zivin R.A., et al. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J. Immunol. Jun 1 1992, 148(11):3461-3468.
21. Herold K.C., Burton J.B., Francois F., Poumian-Ruiz E., Glandt M., Bluestone J.A. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J. Clin. Invest. Feb 2003, 111(3):409-418.
22. Wiczling P., Rosenzweig M., Vaickus L., Jusko W.J. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J. Clin. Pharmacol. May 2010, 50(5):494-506.
23. Ochi H., Abraham M., Ishikawa H., Frenkel D., Yang K., Basso A., et al. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J. Neurol. Sci. Nov 15 2008, 274(1-2):9-12.
24. da Cunha A.P., Weiner H.L. Induction of immunological tolerance by oral anti-CD3. Clin. Dev. Immunol. 2012, 2012:425021.
25. Ochi H., Abraham M., Ishikawa H., Frenkel D., Yang K., Basso A.S., et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+T cells. Nat. Med. Jun 2006, 12(6):627-635.
26. Ishikawa H., Ochi H., Chen M.L., Frenkel D., Maron R., Weiner H.L. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes Aug 2007, 56(8):2103-2109.
27. Ilan Y., Zigmond E., Lalazar G., Dembinsky A., Ben Ya'acov A., Hemed N., et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J. Clin. Immunol. Jan 2010, 30(1):167-177.
28. Penaranda C., Tang Q., Bluestone J.A. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J. Immunol. Aug 15 2011, 187(4):2015-2022.
29. You S., Zuber J., Kuhn C., Baas M., Valette F., Sauvaget V., et al. Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing. Am. J. Transplant. Nov 2012, 12(11):2909-2919.
30. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2years after onset of type 1 diabetes. Diabetes Jun 2005, 54(6):1763-1769.
31. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. May 30 2002, 346(22):1692-1698.
32. Bisikirska B., Colgan J., Luban J., Bluestone J.A., Herold K.C. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+ CD25+ Tregs. J. Clin. Invest. Oct 2005, 115(10):2904-2913.
33. Keymeulen B., Candon S., Fafi-Kremer S., Ziegler A., Leruez-Ville M., Mathieu C., et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood Feb 11 2010, 115(6):1145-1155.
34. Ablamunits V., Bisikirska B., Herold K.C. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur. J. Immunol. Oct 2010, 40(10):2891-2901.
35. Belghith M., Bluestone J.A., Barriot S., Mégret J., Bach J.F., Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. Sep 2003, 9(9):1202-1208.
36. You S., Leforban B., Garcia C., Bach J.F., Bluestone J.A., Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl. Acad. Sci. U. S. A. Apr 10 2007, 104(15):6335-6340.
37. Esplugues E., Huber S., Gagliani N., Hauser A.E., Town T., Wan Y.Y., et al. Control of TH17 cells occurs in the small intestine. Nature Jul 17 2011, 475(7357):514-518.
38. Waldron-Lynch F., Henegariu O., Deng S., Preston-Hurlburt P., Tooley J., Flavell R., et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci. Transl. Med. 2012 Jan. 25, 4(118). (118ra12).
39. Hale G., Rebello P., Al Bakir I., Bolam E., Wiczling P., Jusko W.J., et al. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J. Clin. Pharmacol. Nov 2010, 50(11):1238-1248.
40. Sprangers B., Van der Schueren B., Gillard P., Mathieu C. Otelixizumab in the treatment of type 1 diabetes mellitus. Immunotherapy Nov 2011, 3(11):1303-1316.
41. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet Aug 6 2011, 378(9790):487-497.
42. Herold K.C., Gitelman S.E., Willi S.M., Gottlieb P.A., Waldron-Lynch F., Devine L., et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia Oct 21 2012, [Epub ahead of print].
43. ClinicalTrials.gov Protégé Encore study-clinical trial of teplizumab (MGA031) in children and adults with recent-onset type 1 diabetes mellitus (accessed 2012 Dec 10). http://www.clinicaltrials.gov/ct2/show/NCT00920582/.
44. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. Jun 23 2005, 352(25):2598-2608.
45. Keymeulen B., Walter M., Mathieu C., Kaufman L., Gorus F., Hilbrands R., et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia Apr 2010, 53(4):614-623.
46. GSK press release GlaxoSmithKline and Tolerx announce Phase III DEFEND-1 study of otelixizumab in Type 1 diabetes did not meet is primary end point (accessed 2011 June 9). http://us.gsk.com/html/media-news/pressreleases/2011/2011_pressrelease_10039.htm.
47. ClinicalTrials.gov Trial of otelixizumab for adults with newly diagnosed type 1 diabetes mellitus (autoimmune): DEFEND-1 (accessed 2012 Dec 10). http://www.clinicaltrials.gov/ct2/show/NCT00678886/.
48. ClinicalTrials.gov Trial of otelixizumab for adolescents and adults with newly diagnosed type 1 diabetes mellitus (autoimmune): DEFEND-2 (accessed 2012 Dec 10). http://www.clinicaltrials.gov/ct2/show/NCT01123083/.
49. Palmer J.P., Fleming G.A., Greenbaum C.J., Herold K.C., Jansa L.D., Kolb H., et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes Jan 2004, 53(1):250-264.
50. Herold K.C., Gitelman S., Greenbaum C., Puck J., Hagopian W., Gottlieb P., et al. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5years. Clin. Immunol. Aug 2009, 132(2):166-173.
51. Madsbad S., Krarup T., Faber O.K., Binder C., Regeur L. The transient effect of strict glycaemic control on beta cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia Jan 1982, 22(1):16-20.
52. Akirav E.M., Lebastchi J., Galvan E.M., Henegariu O., Akirav M., Ablamunits V., et al. Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc. Natl. Acad. Sci. U. S. A. Nov 22 2011, 108(47):19018-19023.
53. Lebastchi J., Deng S., Lebastchi A.H., Beshar I., Gitelman S., Willi S., et al. Immune therapy and beta cell death in type 1 diabetes. Diabetes 2013, [in press].
54. Bougneres P.F., Carel J.C., Castano L., Boitard C., Gardin J.P., Landais P., et al. Factors associated with early remission of type 1 diabetes in children treated with cyclosporine. N. Engl. J. Med. Mar 17 1988, 318(11):663-670.
55. ClinicalTrials.gov Teplizumab for prevention of type 1 diabetes in relatives "at-risk" (accessed 2012 Dec 10). http://www.clinicaltrials.gov/ct2/show/NCT01030861/
56. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann. Intern. Med. Apr. 1 1998, 128(7):517-523.
57. Patterson C.C., Dahlquist G.G., Gyürüs E., Green A., Soltész G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet Jun. 13 2009, 373(9680):2027-2033. EURODIAB Study Group.
58. ClinicalTrials.gov Autoimmunity-blocking antibody for tolerance in recently diagnosed type 1 diabetes (AbATE) (accessed 2012 Dec 10). http://www.clinicaltrials.gov/ct2/show/NCT00129259/.
59. Gitelman S. Treatment of Type 1 Diabetes - Update on Clinical Trials. The AbATE Trial (anti-CD3 mAb). Oral presentation at: American Diabetes Association's 71st Scientific Sessions Jun 28 2011, (San Diego, CA).
60. Herold K.C., Ehlers M., Boyle K., McNamara J., Gitelman S., Gottlieb P., et al. Metabolic parameters at baseline identify clinical responders to teplizumab 2years after diagnosis of type 1 diabetes. Oral presentation at: EASD Annual Meeting Oct. 3 2012, (Berlin, Germany).
61. Ludvigsson J., Hagopian W., Carlin D., King K.L., Johnson S., Bonvini E., et al. Teplizumab preserves C-peptide in subjects with type 1 diabetes: 2-year results from the Protégé study. Oral Presentation at: EASD Annual Meeting Oct. 4 2012, (Berlin, Germany).
62. Gottschalk S., Rooney C.M., Heslop H.E. Post-transplant lymphoproliferative disorders. Annu. Rev. Med. 2005, 56:29-44.
63. Mortensen H.B., Hougaard P., Swift P., Hansen L., Holl R.W., Hoey H., et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care Aug 2009, 32(8):1384-1390.
64. Beck R.W., Tamborlane W.V., Bergenstal R.M., Miller K.M., Dubose S.N., Hall C.A., et al. The T1D exchange clinic registry. J. Clin. Endocrinol. Metab. Dec 2012, 97(12):4383-4389.
65. Campbell-Thompson M., Wasserfall C., Montgomery E.L., Atkinson M.A., Kaddis J.S. Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes. JAMA Dec 12 2012, 308(22):2337-2339.